ProCE Banner Activity

CME

Cancer Conversations
PARP Inhibitors in Ovarian Cancer

Case Challenge
Multimedia
Watch this on-demand webcast of a live CCO webinar to hear a panel of experts discuss the current application of PARP inhibitors in ovarian cancer, including areas of consensus and the latest data informing open questions.

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: November 05, 2021

Expiration: November 04, 2022

No longer available for credit.

Share

Faculty

Ursula Matulonis

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Robert E. Coleman

Robert E. Coleman, MD, FRCP

Professor and Honorary Consultant Medical Oncologist
Cancer Clinical Trials Centre
Academic Unit of Clinical Oncology
Weston Park Hospital
Sheffield, England

Kathleen N. Moore

Kathleen N. Moore, MD, MS

Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director
Associate Director Clinical Research
Stephenson Cancer Center at OU Health
Oklahoma City, Oklahoma

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Target Audience

This educational program is intended for gynecologic oncologists, medical oncologists, and other healthcare providers who care for patients with ovarian cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss the current PARP inhibitor indications in ovarian cancer and how those indications can shape treatment plans
  • Evaluate current and emerging practice-changing clinical data on PARP inhibition as single-agent or combination therapies in ovarian cancer
  • Select maintenance therapy for patients with ovarian cancer with or without BRCA mutations or other homologous recombination repair deficiencies in the frontline and relapsed settings

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Ursula Matulonis, MD, has disclosed that she has received consulting fees from GlaxoSmithKline, Merck, NextCure, and Novartis.

Faculty Disclosure

Primary Author

Robert E. Coleman, MD, FRCP

Professor and Honorary Consultant Medical Oncologist
Cancer Clinical Trials Centre
Academic Unit of Clinical Oncology
Weston Park Hospital
Sheffield, England

Robert L. Coleman, MD, FACOG, FACS, has disclosed that he has received funds for research support from AbbVie, AstraZeneca, Clovis, Genmab, Immunogen, Merck, and Roche/Genentech; consulting fees from AbbVie, Agenus, Alkermes, Aravive, AstraZeneca, Clovis, Deciphera, Epsilogen, Genmab, Immunogen, Merck, Novocure, and Roche/Genentech; and fees for non-CME/CE services from AstraZeneca.

Kathleen N. Moore, MD, MS

Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director
Associate Director Clinical Research
Stephenson Cancer Center at OU Health
Oklahoma City, Oklahoma

Kathleen Moore, MD, has disclosed that she has received consulting fees from Alkernes, Aravive, AstraZeneca, Blueprint, Eisai, Elevar, IMab, Immunogen, Mereo, Merck, Mersana, Myriad, OncoMed, Sorrento, and VBL Therapeutics.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Jerfiz Constanzo, PhD, MBA

Scientific Director

Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 05, 2021, through November 04, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to educate gynecologic oncologists, medical oncologists, and other healthcare professionals about the recent developments in the care of ovarian cancer and incorporating new data and new therapies into their patient treatment plans.